Thrombophlebitis of superficial veins in acute phase
Conditions
Interventions
High-dose group:Phlebitis Granules: Take 200-300 mL of boiling water for oral administration. Take 1 small box (containing 2 packets) at a time, three times a day.
Low-dose group:Phlebitis Granules and simulator, stirred with 200-300mL boiling water, once 1 small box (containing 1 packet of Phlebitis Granules + 1 packet of Phlebitis Granules simulator), three ti
Placebo group:Venous phlebitis granule simulator, take with 200-300 mL of boiling water, one small box (containing 2 bags) at a time, three times a day.
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for acute thrombophlebitis of superficial veins in Western medicine, classified as limb thrombophlebitis of superficial veins or thoracoabdominal wall thrombophlebitis of superficial veins; (2) Meets the diagnostic criteria for the syndrome of blood heat and stasis in traditional Chinese medicine; (3) Duration of illness at the time of consultation =5 days; (4) No prior treatment for the condition; (5) Pain VAS score at the time of consultation =40mm (integer value); (6) Age between 18-70 years, gender; (7) Informed consent and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Migratory thrombophlebitis of superficial veins; 2. Lesions with target vessels complicated by active ulcers that have not healed or other severe conditions requiring surgical intervention; 3. Patients with deep vein thrombosis; 4. Patients with skin and soft tissue infections, such as erysipelas, acute lymphangitis, or acute cellulitis; 5. Patients with neutrophil count exceeding the upper limit of normal in blood tests; 6. Patients with Cr exceeding the upper limit of normal or ALT or AST exceeding 1.5 times the upper limit of normal; 7. Patients with severe primary diseases of important organs or systems, such as heart, liver, kidney, or hematopoietic system; 8. Pregnant women, women planning pregnancy within six months, or breastfeeding women; 9. Patients with mental illness or cognitive impairment; 10. Patients with known allergies to components of the investigational drug or with a history of allergic constitution; 11. Patients with suspected or confirmed history of alcohol addiction or drug abuse; 12. Patients who have participated in other clinical trials within the past 30 days; 13. Patients deemed unsuitable for participation in this clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time to disappearance of clinical symptoms and their disappearance rate.;Changes in pain VAS score compared to before medication.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine (TCM) Syndrome Efficacy;Efficacy;Time and rate of disappearance of single symptoms;The changes in blood inflammatory markers compared to baseline.; | — |
Countries
China
Contacts
Public ContactLiu Guobin
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed